

Joann V Pinkerton

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/816869/publications.pdf>

Version: 2024-02-01

86
papers

3,970
citations

168829

31
h-index

134545

62
g-index

86
all docs

86
docs citations

86
times ranked

3047
citing authors

#	ARTICLE	IF	CITATIONS
1	Risks of Testosterone for Postmenopausal Women. <i>Endocrinology and Metabolism Clinics of North America</i> , 2021, 50, 139-150.	1.2	1
2	Concerns about safety and efficacy of compounded bioidentical hormone therapy. <i>Menopause</i> , 2021, 28, 847-849.	0.8	3
3	Selective Estrogen Receptor Modulators in Gynecology Practice. <i>Clinical Obstetrics and Gynecology</i> , 2021, 64, 803-812.	0.6	6
4	Approach to Managing a Postmenopausal Patient. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 3792-3806.	1.8	3
5	Workshop on normal reference ranges for estradiol in postmenopausal women: commentary from The North American Menopause Society on low-dose vaginal estrogen therapy labeling. <i>Menopause</i> , 2020, 27, 611-613.	0.8	5
6	Hormone therapy and sarcopenia: implications for the prevention of frailty as women age. <i>Menopause</i> , 2020, 27, 496-497.	0.8	2
7	Response to Letter to the Editor: "Global Consensus Position Statement on the Use of Testosterone Therapy for Women". <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e2313-e2314.	1.8	2
8	Underlying Breast Cancer Risk and Menopausal Hormone Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e2299-e2307.	1.8	20
9	The National Academies of Science, Engineering, and Medicine (NASEM) Report on Compounded Bioidentical Hormone Therapy. <i>Menopause</i> , 2020, 27, 1199-1201.	0.8	6
10	Vaginal estrogen: Underprescribed treatment for an underdiagnosed condition of menopausal women. <i>Maturitas</i> , 2019, 121, 83-85.	1.0	0
11	Global Consensus Position Statement on the Use of Testosterone Therapy for Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 4660-4666.	1.8	147
12	Global Consensus Position Statement on the use of Testosterone Therapy for Women. <i>Maturitas</i> , 2019, 128, 89-93.	1.0	12
13	Global Consensus Position Statement on the Use of Testosterone Therapy for Women. <i>Journal of Sexual Medicine</i> , 2019, 16, 1331-1337.	0.3	22
14	Global Consensus Position Statement on the Use of Testosterone Therapy for Women. <i>Climacteric</i> , 2019, 22, 429-434.	1.1	50
15	Management of Menopause and the Role For Hormone Therapy. <i>Clinical Obstetrics and Gynecology</i> , 2019, 62, 677-686.	0.6	5
16	Concern about US Preventive Services Task Force recommendation on hormone therapy for the primary prevention of chronic conditions in postmenopausal women. <i>Menopause</i> , 2018, 25, 476.	0.8	4
17	Management of Menopausal Symptoms for Women Who Are at High Risk of Thrombosis. <i>Clinical Obstetrics and Gynecology</i> , 2018, 61, 260-268.	0.6	9
18	Overall Safety of Ospemifene in Postmenopausal Women from Placebo-Controlled Phase 2 and 3 Trials. <i>Journal of Women's Health</i> , 2018, 27, 14-23.	1.5	48

#	ARTICLE	IF	CITATIONS
19	Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women's Sexual Health. <i>Menopause</i> , 2018, 25, 596-608.	0.8	143
20	Why Should Clinicians Be Concerned About Prescribing Compounded Hormones for Menopausal Women?. <i>Journal of Women's Health</i> , 2018, 27, 847-849.	1.5	0
21	The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review. <i>Menopause</i> , 2018, 25, 837-847.	0.8	105
22	Not time to abandon use of local vaginal hormone therapies. <i>Menopause</i> , 2018, 25, 855-858.	0.8	9
23	Tissue-selective Estrogen Complex for Menopausal Hormone Therapy. <i>Clinical Obstetrics and Gynecology</i> , 2018, 61, 463-469.	0.6	5
24	Foreword: Managing Menopause by Combining Evidence With Clinical Judgment. <i>Clinical Obstetrics and Gynecology</i> , 2018, 61, 417-418.	0.6	0
25	Time to first occurrence of breast pain and vaginal bleeding in phase 3 trials of CE/BZA. <i>Menopause</i> , 2017, 24, 1372-1377.	0.8	2
26	Safety and benefit considerations for menopausal hormone therapy. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 941-954.	1.0	14
27	Vaginal estrogen in the treatment of genitourinary syndrome of menopause and risk of endometrial cancer: an assessment of recent studies provides reassurance. <i>Menopause</i> , 2017, 24, 1329-1332.	0.8	14
28	Managing Menopausal Symptoms and Associated Clinical Issues in Breast Cancer Survivors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 3647-3661.	1.8	89
29	Changing the conversation about hormone therapy. <i>Menopause</i> , 2017, 24, 991-993.	0.8	4
30	Time to transient and stable reductions in hot flush frequency in postmenopausal women using conjugated estrogens/bazedoxifene. <i>Menopause</i> , 2017, 24, 1011-1016.	0.8	3
31	Changing the conversation about hormone therapy. <i>Climacteric</i> , 2017, 20, 293-295.	1.1	3
32	Hot flush frequency and severity at baseline as predictors of time to transient and stable treatment success: pooled analysis of two CE/BZA studies. <i>Menopause</i> , 2017, 24, 1378-1385.	0.8	2
33	Pharmacotherapies for Menopause Management: Hormonal Options. , 2017, , 67-85.		0
34	Conjugated estrogens and bazedoxifene in minority populations: pooled analysis of four phase 3 trials. <i>Menopause</i> , 2016, 23, 611-620.	0.8	2
35	Compounded Bioidentical Hormones in Endocrinology Practice: An Endocrine Society Scientific Statement. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 1318-1343.	1.8	48
36	Update on medical and regulatory issues pertaining to compounded and FDA-approved drugs, including hormone therapy. <i>Menopause</i> , 2016, 23, 215-223.	0.8	29

#	ARTICLE	IF	CITATIONS
37	Pooled Analysis of the Effects of Conjugated Estrogens/Bazedoxifene on Vasomotor Symptoms in the Selective Estrogens, Menopause, and Response to Therapy Trials. <i>Journal of Women's Health</i> , 2016, 25, 1102-1111.	1.5	9
38	Direct and indirect effects of conjugated estrogens/bazedoxifene treatment on quality of life in postmenopausal women. <i>Maturitas</i> , 2016, 94, 173-179.	1.0	6
39	Relationship between changes in vasomotor symptoms and changes in menopause-specific quality of life and sleep parameters. <i>Menopause</i> , 2016, 23, 1060-1066.	0.8	49
40	Ospemifene's effect on vasomotor symptoms: a post hoc analysis of phase 2 and 3 clinical data. <i>Menopause</i> , 2016, 23, 957-964.	0.8	13
41	Timing and persistence of effect of conjugated estrogens/bazedoxifene in postmenopausal women. <i>Menopause</i> , 2016, 23, 1204-1213.	0.8	5
42	Gynecologic Safety of Conjugated Estrogens Plus Bazedoxifene: Pooled Analysis of Five Phase 3 Trials. <i>Journal of Women's Health</i> , 2016, 25, 431-442.	1.5	25
43	Compounded non-FDA-approved menopausal hormone therapy prescriptions have increased. <i>Menopause</i> , 2016, 23, 359-367.	0.8	25
44	Effects of ospemifene on the female reproductive and urinary tracts. <i>Menopause</i> , 2015, 22, 786-796.	0.8	18
45	Ospemifene for the treatment of postmenopausal vulvar and vaginal atrophy: recommendations for clinical use. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2703-2714.	0.9	17
46	Low-dose paroxetine (7.5 mg) improves sleep in women with vasomotor symptoms associated with menopause. <i>Menopause</i> , 2015, 22, 50-58.	0.8	33
47	Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 3975-4011.	1.8	589
48	Evaluation of the Efficacy and Safety of Bazedoxifene/Conjugated Estrogens for Secondary Outcomes Including Vasomotor Symptoms in Postmenopausal Women by Years Since Menopause in the Selective Estrogens, Menopause and Response to Therapy (SMART) Trials. <i>Journal of Women's Health</i> , 2014, 23, 18-28.	1.5	46
49	Sleep parameters and health-related quality of life with bazedoxifene/conjugated estrogens. <i>Menopause</i> , 2014, 21, 252-259.	0.8	44
50	Perspectives on the first randomized sham-controlled trial of stellate ganglion block for hot flashes. <i>Menopause</i> , 2014, 21, 788-791.	0.8	4
51	Evaluation of the direct and indirect effects of bazedoxifene/conjugated estrogens on sleep disturbance using mediation modeling. <i>Menopause</i> , 2014, 21, 243-251.	0.8	13
52	Evaluation of the measurement model and clinically important differences for menopause-specific quality of life associated with bazedoxifene/conjugated estrogens. <i>Menopause</i> , 2014, 21, 815-822.	0.8	12
53	Clinical effects of selective estrogen receptor modulators on vulvar and vaginal atrophy. <i>Menopause</i> , 2014, 21, 309-319.	0.8	33
54	Phase 3 randomized controlled study of gastroretentive gabapentin for the treatment of moderate-to-severe hot flashes in menopause. <i>Menopause</i> , 2014, 21, 567-573.	0.8	43

#	ARTICLE	IF	CITATIONS
55	Effects of Bazedoxifene/Conjugated Estrogens on the Endometrium and Bone: A Randomized Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E189-E198.	1.8	126
56	Think Twice Before Prescribing Custom-Compounded Bioidentical Hormone Therapy. <i>Journal of Women's Health</i> , 2014, 23, 631-633.	1.5	4
57	Use of SERMs for treatment in postmenopausal women. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2014, 142, 142-154.	1.2	119
58	Menopause-specific quality of life across varying menopausal populations with conjugated estrogens/bazedoxifene. <i>Maturitas</i> , 2014, 78, 212-218.	1.0	17
59	Osteoporosis Treatment and Prevention for Postmenopausal Women. <i>Clinical Obstetrics and Gynecology</i> , 2013, 56, 711-721.	0.6	29
60	Breast density changes in a randomized controlled trial evaluating bazedoxifene/conjugated estrogens. <i>Menopause</i> , 2013, 20, 138-145.	0.8	83
61	Breast Effects of Bazedoxifene-Conjugated Estrogens. <i>Obstetrics and Gynecology</i> , 2013, 121, 959-968.	1.2	105
62	Desvenlafaxine compared with placebo for treatment of menopausal vasomotor symptoms. <i>Menopause</i> , 2013, 20, 28-37.	0.8	39
63	Maintenance of the efficacy of desvenlafaxine in menopausal vasomotor symptoms. <i>Menopause</i> , 2013, 20, 38-46.	0.8	26
64	Cardiovascular, cerebrovascular, and hepatic safety of desvenlafaxine for 1 year in women with vasomotor symptoms associated with menopause. <i>Menopause</i> , 2013, 20, 47-56.	0.8	14
65	Tissue-Selective Estrogen Complex Bazedoxifene and Conjugated Estrogens for the Treatment of Menopausal Vasomotor Symptoms. <i>Drugs</i> , 2011, 71, 1649-1657.	4.9	7
66	Pharmacological therapy for abnormal uterine bleeding. <i>Menopause</i> , 2011, 18, 459-467.	0.8	39
67	Menstrual cycle-related exacerbation of disease. <i>American Journal of Obstetrics and Gynecology</i> , 2010, 202, 221-231.	0.7	71
68	Reproductive aging, menopause, and health outcomes. <i>Annals of the New York Academy of Sciences</i> , 2010, 1204, 169-178.	1.8	30
69	Treatment of postmenopausal osteoporosis in a patient with celiac disease. <i>Nature Reviews Endocrinology</i> , 2010, 6, 167-171.	4.3	6
70	Bazedoxifene when paired with conjugated estrogens is a new paradigm for treatment of postmenopausal women. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 1613-1621.	1.9	14
71	Postmenopausal Hormone Therapy: An Endocrine Society Scientific Statement. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, s1-s66.	1.8	512
72	Endometrial safety. <i>Menopause</i> , 2010, 17, 642-653.	0.8	53

#	ARTICLE	IF	CITATIONS
73	Advances in the Treatment of Menopausal Symptoms. <i>Women's Health</i> , 2009, 5, 361-384.	0.7	45
74	Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. <i>Fertility and Sterility</i> , 2009, 92, 1025-1038.	0.5	239
75	Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis. <i>Menopause</i> , 2009, 16, 1102-1108.	0.8	71
76	Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens. <i>Menopause</i> , 2009, 16, 1116-1124.	0.8	174
77	Bazedoxifene, a selective estrogen receptor modulator. <i>Menopause</i> , 2009, 16, 1109-1115.	0.8	95
78	Estrogen Agonists/Antagonists in Combination with Estrogen for Prevention and Treatment of Menopause-Associated Signs and Symptoms. <i>Women's Health</i> , 2008, 4, 257-268.	0.7	15
79	Does addition of gabapentin to antidepressant therapy improve control of hot flashes?. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2007, 3, 566-567.	2.9	1
80	Combination therapy for treatment of osteoporosis: A review. <i>American Journal of Obstetrics and Gynecology</i> , 2007, 197, 559-565.	0.7	24
81	Perspective on menopausal vasomotor symptoms, CAM, and the SWAN. <i>Menopause</i> , 2007, 14, 601-605.	0.8	2
82	Vasomotor Symptoms in Menopause: Where We've Been and Where We're Going. <i>Journal of Women's Health</i> , 2006, 15, 135-145.	1.5	24
83	Estrogen and Cognition, with a Focus on Alzheimer's Disease. <i>Seminars in Reproductive Medicine</i> , 2005, 23, 172-179.	0.5	52
84	Influence of raloxifene on the efficacy of an estradiol-releasing ring for treating vaginal atrophy in postmenopausal women. <i>Menopause</i> , 2003, 10, 45-52.	0.8	31
85	Treatment of urogenital atrophy with low-dose estradiol: preliminary results. <i>Menopause</i> , 2002, 9, 179-187.	0.8	102
86	Selective estrogen receptor modulators used for postmenopausal women. , 0, , 142-148.		0